{
  "metadata": {
    "generation_timestamp": "2025-09-03T22:55:08.575212",
    "total_communities": 4,
    "source_graph": "output_data/graph/annual_report_text (1)_graph.json",
    "source_communities": "output_data/communities/annual_report_text (1)_communities.json",
    "llm_model": "llama3.1:latest",
    "report_type": "KYC_AML_Risk_Assessment",
    "analysis_focus": "Business Intelligence and Compliance Risk"
  },
  "risk_summary": {
    "total_entities": 40,
    "high_risk_clusters": 1,
    "average_cluster_size": 10.0
  },
  "summaries": [
    {
      "community_id": 0,
      "size": 21,
      "type_counts": {
        "COMPANY": 1,
        "PRODUCT": 2,
        "OTHER": 3,
        "CLIENT": 5,
        "UNKNOWN": 10
      },
      "summary": "**THEME:** Global Health Technology and Services Provider\n\n**KEY ENTITIES:**\n\n* IBA (World leader in particle accelerator technology): Primary entity with diverse business interests\n* Industrial Solutions and RadioPharma Solutions: Key subsidiaries or business units\n* Hospitals and Health care professionals: Critical customers and partners\n* Customers and partners around the world: Global network of clients and collaborators\n\n**RELATIONSHIPS:**\n\n* IBA's ownership and market presence in particle accelerator technology and innovative cancer solutions\n* Partnerships with hospitals, health care professionals, and customers worldwide\n* Collaborations with regulatory bodies for compliance and research purposes\n* Upgrades and operations in hospitals globally, indicating a significant presence in the healthcare sector\n\n**RISK ASSESSMENT:**\n\n* High risk of exposure to global sanctions and embargoes due to partnerships with entities in various countries\n* Potential risks associated with collaboration with health care professionals, including compliance with medical regulations and confidentiality requirements\n* IBA's involvement in research and development may attract unwanted attention from competitors or malicious actors\n* Regulatory bodies' oversight is a positive indicator, but ongoing monitoring of compliance is essential.",
      "sample_nodes": [
        "IBA",
        "Particle accelerator technology",
        "Dosimetry equipment",
        "Industrial Solutions",
        "RadioPharma Solutions",
        "World leader in particle accelerator technology",
        "Hospitals",
        "Health care professionals",
        "Customers and partners",
        "Society",
        "Planet",
        "particle accelerator technology",
        "innovative solutions for the diagnosis and treatment of cancer",
        "particle accelerators and dosimetry equipment",
        "hospitals around the world",
        "customers and partners around the world",
        "health care professionals and patients around the world",
        "industrial applications such as sterilization of medical devices",
        "new partnerships and collaborations",
        "new products and services",
        "information about the company's activities and operations"
      ],
      "statistics": {
        "total_edges": 23,
        "internal_edges": 10,
        "external_edges": 13,
        "connectivity_ratio": 0.435
      },
      "top_entity_types": [
        "UNKNOWN: 10",
        "CLIENT: 5",
        "OTHER: 3",
        "PRODUCT: 2",
        "COMPANY: 1"
      ]
    },
    {
      "community_id": 1,
      "size": 6,
      "type_counts": {
        "EMPLOYEE": 1,
        "SHAREHOLDER": 1,
        "UNKNOWN": 4
      },
      "summary": "**THEME:** Financial Health Assessment and Risk Indicators\n\n**KEY ENTITIES:**\n\n* Employees (key personnel involved in financial decision-making)\n* Shareholders (individuals or entities with significant ownership stakes)\n\n**RELATIONSHIPS:**\n\n* IBA's research and development of innovative solutions is a precursor to expansion into new markets and industries, indicating potential financial investments.\n* The planned expansion into new markets and industries suggests strategic growth initiatives, which may involve increased financial risk.\n* Completed research and development projects imply successful innovation, but also potential financial commitments.\n\n**RISK ASSESSMENT:**\n\n* Potential red flags include:\n\t+ Unusual or unexplained transactions related to research and development projects\n\t+ Inconsistent or incomplete reporting on expansion plans and market penetration\n\t+ Shareholder involvement in high-risk investments or business ventures\n* Compliance considerations:\n\t+ Ensure accurate and timely reporting of financial activities, including research and development expenses\n\t+ Verify the legitimacy and transparency of shareholder involvement in business decisions\n\t+ Monitor for potential money laundering risks associated with large-scale transactions or investments",
      "sample_nodes": [
        "Employees",
        "Shareholders",
        "research and development of innovative solutions",
        "new markets and industries",
        "expansion into new markets and industries",
        "research and development projects"
      ],
      "statistics": {
        "total_edges": 4,
        "internal_edges": 0,
        "external_edges": 4,
        "connectivity_ratio": 0.0
      },
      "top_entity_types": [
        "UNKNOWN: 4",
        "EMPLOYEE: 1",
        "SHAREHOLDER: 1"
      ]
    },
    {
      "community_id": 2,
      "size": 5,
      "type_counts": {
        "LICENSE": 1,
        "REGULATOR": 1,
        "UNKNOWN": 3
      },
      "summary": "**THEME:** Regulatory Compliance and Risk Management\n\n**KEY ENTITIES:**\n\n* **Certified B Corporation (B Corp)**: A for-profit business certified to meet rigorous standards of social and environmental responsibility.\n* **Regulators (SEC, FINRA, FCA, CFTC)**: Government agencies responsible for overseeing financial markets and institutions.\n* **Regulatory bodies around the world**: International organizations that set standards and guidelines for regulatory compliance.\n\n**RELATIONSHIPS:**\n\n* IBA —regulated_by→ Regulatory bodies around the world: Indicates a need to comply with international regulations and standards.\n* IBA —supervised_by→ Supervisory authorities: Suggests ongoing monitoring and oversight by regulatory agencies.\n* IBA —filed→ Regulatory filings and reports: Highlights the importance of accurate and timely reporting to regulatory bodies.\n\n**RISK ASSESSMENT:**\n\n* **Sanctions risk**: The presence of B Corp entities may indicate a higher risk of sanctions exposure due to their global operations.\n* **Compliance risk**: Inaccurate or incomplete regulatory filings and reports could lead to fines, penalties, or reputational damage.\n* **Reputation risk**: Failure to meet social and environmental responsibility standards could harm the reputation of B Corp entities.",
      "sample_nodes": [
        "Certified B Corporation (B Corp)",
        "Regulators (SEC, FINRA, FCA, CFTC)",
        "regulatory bodies around the world",
        "supervisory authorities",
        "regulatory filings and reports"
      ],
      "statistics": {
        "total_edges": 3,
        "internal_edges": 0,
        "external_edges": 3,
        "connectivity_ratio": 0.0
      },
      "top_entity_types": [
        "UNKNOWN: 3",
        "LICENSE: 1",
        "REGULATOR: 1"
      ]
    },
    {
      "community_id": 3,
      "size": 8,
      "type_counts": {
        "OTHER": 2,
        "UNKNOWN": 6
      },
      "summary": "**THEME:** Healthcare Technology and Services\n\n**KEY ENTITIES:**\n\n* IBA (Proton Therapy, Dosimetry) - a key player in healthcare technology\n* Health care professionals - critical stakeholders in the delivery of proton therapy services\n* Belgium (headquarters, over thirty years ago) - indicates a long-standing presence in the region\n* Financial results and performance, annual reports and corporate brochures - essential for assessing IBA's business health\n\n**RELATIONSHIPS:**\n\n* Collaborations with healthcare professionals suggest a strong focus on delivering high-quality services\n* Presence in Belgium (headquarters, founded, established) indicates a significant investment in the region\n* Reporting of financial results and publication of annual reports demonstrate transparency and compliance with regulatory requirements\n\n**RISK ASSESSMENT:**\n\n* The concentration of entities related to IBA's healthcare technology business may indicate a high-risk exposure to market fluctuations or industry-specific risks.\n* Compliance considerations include ensuring adherence to regulations governing the delivery of proton therapy services, as well as maintaining accurate financial reporting and transparency.\n* Potential red flags include any inconsistencies in financial reporting, unexplained changes in business relationships, or indications of non-compliance with regulatory requirements.",
      "sample_nodes": [
        "Proton Therapy",
        "Dosimetry",
        "health care professionals",
        "Belgium (headquarters)",
        "Belgium",
        "Belgium (over thirty years ago)",
        "financial results and performance",
        "annual reports and corporate brochures"
      ],
      "statistics": {
        "total_edges": 6,
        "internal_edges": 0,
        "external_edges": 6,
        "connectivity_ratio": 0.0
      },
      "top_entity_types": [
        "UNKNOWN: 6",
        "OTHER: 2"
      ]
    }
  ]
}